| Name | Title | Contact Details |
|---|---|---|
Dennis Whalen |
Vice President of Technology and Chief Technology Officer | Profile |
At Luitpold Animal Health, we are totally committed to advancing the cause of better animal health.
We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. We have initiated two Phase 3b clinical trials of XHANCE for a follow-on indication for the treatment of chronic sinusitis and expect top-line results by the end of 2021 from one trial and in the first half of 2022 from the second trial. If successful, we believe XHANCE would be the first drug therapy product approved by the FDA for the treatment of chronic sinusitis. As of February 28, 2021, we had a total of 204 full-time employees and three part-time employees. A majority of our employees are field-based, in customer-facing roles. Culture is a critical element in the management of our organization. Our talented employees, known as colleagues, are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.
BeyondSpring is a Global, Clinical-Stage. Bio-pharmaceutical Company. Developing Innovative Immuno-Oncology Cancer Therapies with a Robust Pipeline from Internal Development and from Collaboration with University of Washington in De Novo Drug Discovery Using a Ubiquitination Platform.
Indago is developing smart surgical tools that enable physicians to focus on healthcare, not hardware. Our mission: to create the OR of the future.
Your patient journey.Made even better. We connect specialty pharma to its vendors within one easy gateway. No app needed. See it for yourself All your vendors. All in one place. ic_24px/insurance Capture missing info No more chasing down incomplete pap...